Abstract
The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (rdf) in the prophylaxis of radiation-induced nausea and vomiting (rinv). Rapidly dissolving film formulations facilitate drug delivery in circumstances in which swallowing the medication might be difficult for the patient. Patients undergoing palliative radiotherapy at risk for rinv were prescribed ondansetron rdf 8 mg twice daily while on treatment and were asked to complete a nausea and vomiting-specific daily diary, the Functional Living Index-Emesis (flie), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C15 Palliative (qlq-C15-pal). Patients were categorized as receiving primary or secondary prophylaxis based on whether they had already experienced emetic episodes. "Overall control" was defined as a maximum increase of 2 episodes of nausea or vomiting from baseline. "Acute phase" was defined as the days during radiation until the first day after radiation; "delayed phase" was defined as days 2-10 after radiation. The study accrued 30 patients. Rates of overall control for nausea and for vomiting during the acute phase in the primary prophylaxis group were 88% and 93% respectively; during the delayed phase, they were 73% and 75%. Rates of overall control for nausea and for vomiting during the acute phase in the secondary prophylaxis group were both 100%; during the delayed phase, they were 50%. The number of nausea and vomiting episodes was found to be significantly correlated with the flie and qlq-C15-pal questionnaires. Ondansetron rdf is effective for the prophylaxis of rinv.
Highlights
The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film in the prophylaxis of radiation-induced nausea and vomiting
Ondansetron rdf is effective for the prophylaxis of rinv
Guidelines cooperatively issued by the American Society of Clinical Oncology, the Multinational Association of Supportive Care in Cancer, and the European Society for Medical Oncology recommend a 5-hydroxytryptamine-3 www.current-oncology.com receptor antagonist for the prophylaxis or rescue therapy of rinv in high, moderate, and low emetogenic risk categories[2,7,8]
Summary
The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (rdf) in the prophylaxis of radiation-induced nausea and vomiting (rinv). Depending on the anatomic site of treatment, radiationinduced nausea and vomiting (rinv) can affect 40%–80% of patients undergoing radiation therapy[1]. Radiation-induced nausea and vomiting can cause delay or discontinuation of radiation treatment[2,3,4], which can increase the need for medical care and be burdensome to the medical system[5,6]. Patients can present with comorbidities such as dysphagia or pre-existing nausea and vomiting from chemotherapy or opioid usage. Those symptoms can lead to difficulty in taking the oral pills
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
